- Home
- KORE vs MRSN Comparison
KORE vs MRSN Comparison
Compare KORE & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KORE
- MRSN
- Stock Information
- Founded
- KORE 2003
- MRSN 2001
- Country
- KORE United States
- MRSN United States
- Employees
- KORE N/A
- MRSN N/A
- Industry
- KORE Telecommunications Equipment
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- KORE Consumer Discretionary
- MRSN Health Care
- Exchange
- KORE Nasdaq
- MRSN Nasdaq
- Market Cap
- KORE 45.0M
- MRSN 37.0M
- IPO Year
- KORE N/A
- MRSN 2017
- Fundamental
- Price
- KORE N/A
- MRSN $9.44
- Analyst Decision
- KORE Hold
- MRSN Strong Buy
- Analyst Count
- KORE 2
- MRSN 3
- Target Price
- KORE $2.75
- MRSN $33.00
- AVG Volume (30 Days)
- KORE 23.7K
- MRSN 49.0K
- Earning Date
- KORE 11-18-2025
- MRSN 11-12-2025
- Dividend Yield
- KORE N/A
- MRSN N/A
- EPS Growth
- KORE N/A
- MRSN N/A
- EPS
- KORE N/A
- MRSN N/A
- Revenue
- KORE $285,636,000.00
- MRSN $34,769,000.00
- Revenue This Year
- KORE $4.46
- MRSN N/A
- Revenue Next Year
- KORE $5.94
- MRSN N/A
- P/E Ratio
- KORE N/A
- MRSN N/A
- Revenue Growth
- KORE 0.24
- MRSN 16.14
- 52 Week Low
- KORE $1.10
- MRSN $5.21
- 52 Week High
- KORE $4.88
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- KORE N/A
- MRSN 62.93
- Support Level
- KORE N/A
- MRSN $7.85
- Resistance Level
- KORE N/A
- MRSN $8.35
- Average True Range (ATR)
- KORE 0.00
- MRSN 0.37
- MACD
- KORE 0.00
- MRSN 0.00
- Stochastic Oscillator
- KORE 0.00
- MRSN 77.70
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.